New research suggests that patients who come off new slimming jabs like Mounjaro or Wegovy may regain lost weight far faster than those who stop traditional diet and exercise programs.
Published data in a prominent medical journal shows that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals using such treatments must be informed of the potential of rapid weight regain when the treatment concludes," warns expert Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight within about 18 months.
Weighing Treatments
The research, which examined dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
Scientists note that individuals who shed pounds through dieting usually see a more gradual creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Experts suggest the mechanism of the drugs explains the amplified weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means hunger is no longer kept in check, making excessive eating far more likely."
A Chronic Issue?
The NHS advise the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians say that, given the likelihood of weight regain, the treatment might need to be ongoing.
This perspective is reinforced by drug manufacturers, who note that the results "underscore the chronic nature of obesity," similar to managing conditions like diabetes.
User Accounts
Users who have come off the jabs report a sudden return of hunger.
"It was like something activating and you become starving," described an individual.
The struggle is worsened if users have not established permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data indicate that a significant number of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Use is more common among females than men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and lasting health benefits likely depends on integrated behavioural changes.
